Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Aug 5, 2025, 2:01 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Despite recent loss and share drop, strong revenue growth and analyst upgrades indicate positive sentiment, similar to previous strong earnings leading to price recoveries in biotech stocks like AXSM.

AI summary

What happened, with direct paths to the underlying reporting

Axsome reported Q2 losses of $0.47 versus $1.07 expected loss. Quarterly sales reached $150.04 million, beating estimates of $140.33 million. Recent approval of SYMBRAVO and ongoing sales of AUVELITY are promising. Analysts maintain positive ratings and raise price targets for AXSM. AXSM shares decreased by 3.4% despite the strong earnings report.

Axsome reported Q2 losses of $0.47 versus $1.07 expected loss.
Quarterly sales reached $150.04 million, beating estimates of $140.33 million.
Recent approval of SYMBRAVO and ongoing sales of AUVELITY are promising.
Analysts maintain positive ratings and raise price targets for AXSM.
AXSM shares decreased by 3.4% despite the strong earnings report.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.